Servier Egypt has launched Tibsovo (ivosidenib), the first targeted therapy available in the country for patients with IDH1-mutated Acute Myeloid Leukemia (AML) and intrahepatic cholangiocarcinoma. The treatment offers a median overall survival of 29.3 months for eligible AML patients and 10.3 months for those with intrahepatic cholangiocarcinoma, according to clinical data. It is approved as a first-line treatment for AML and a second-line option for intrahepatic cholangiocarcinoma.
Servier Egypt has introduced Tibsovo, a drug that targets the IDH1 genetic mutation in tumors, providing an alternative for patients with Acute Myeloid Leukemia (AML), an aggressive blood cancer originating in the bone marrow, and intrahepatic cholangiocarcinoma, a type of bile duct cancer starting inside the liver. This launch marks a significant step in expanding access to treatments addressing unmet medical needs in Egypt, where options have historically been limited for those unable to endure intensive chemotherapy or stem-cell transplantation.
Samy Sinnuqrut, General Manager of Servier Egypt, stated: “Bringing Tibsovo to Egypt is yet another step in Servier’s role to expand access to treatments that address clear medical needs. Our role is to ensure that these advances reach patients in a reliable and timely way.”
The AGILE clinical study showed improved event-free and overall survival for AML patients ineligible for intensive chemotherapy. The ClarIDHy study demonstrated better survival and disease control for intrahepatic cholangiocarcinoma patients. Ibtisam Saad El Din, Professor of Oncology at Cairo University, said: “The availability of Tibsovo gives physicians an important new tool for managing cancers driven by the IDH1 mutation. Identifying the mutation early through routine testing makes a significant difference in choosing the right treatment path.”
Tamer El Nahas, Oncology Consultant and Professor at Cairo University, added: “AML and cholangiocarcinoma often affect patients who cannot tolerate aggressive chemotherapy. Tibsovo provides a scientifically precise option with a more favourable tolerability profile.” Gamal Fathy, Professor of Haematology and Bone Marrow Transplant at the Nasser Institute, noted that the oral therapy delivers sustained clinical responses for AML patients and can reduce reliance on repeated transfusions.
Nearly 70% of Servier’s global research and development investment is focused on oncology. The therapy is recommended by international guidelines, including NCCN and ESMO.
